# T.P. Devarajan

> T.P. Devarajan is a Series B investor at InvAscent backing Health Care. See 4 investments, check sizes, portfolio and contact details. Updated Sep 2026.

- Type: Angel Investor
- Fund: [InvAscent](https://shizune.co/investors/profile/invascent)
- Location: Hyderabad, India
- Total investments: 4
- Last investment: Apr 2022
- Lead investor: 50%
- Last updated: Sep 2026
- LinkedIn: https://www.linkedin.com/in/t-p-devarajan-2596562

T.P. Devarajan is a Series B investor at InvAscent in Hyderabad focused on Health Care and Medical. T.P. Devarajan is the Managing Director of InvAscent.

## Contacts

5 contacts available for T.P. Devarajan: work email, personal email, work phone, personal phone and socials. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-email/t-p-devarajan?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 2 | 50% |
| Medical | 1 | 25% |
| mHealth | 1 | 25% |
| Consulting | 1 | 25% |
| Biotechnology | 1 | 25% |

9 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 1 | 25% |
| Funding Round | 1 | 25% |
| Private Equity | 1 | 25% |
| Venture - Series Unknown | 1 | 25% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| India | 2 | 50% |
| United States | 1 | 25% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Malladi Drugs | Malladi is a manufacturer of active pharmaceutical ingredients in the cough and cold segment of the global pharmaceutical industry and therapeutic segments such as antihistamines, anticonvulsants, antidepressants, and anxiolytics. The company's products and services to the benefit of society. | $32.7M | Private Equity | Apr 25, 2022 |  |
| MediSage | Medisage is a global community of Doctors Connect with Global doctors, watch video case studies by subject matter experts, read latest medical news and discuss patient cases. | $6.3M |  | Apr 13, 2022 |  |
| MediSage | Medisage is a global community of Doctors Connect with Global doctors, watch video case studies by subject matter experts, read latest medical news and discuss patient cases. | $7M | Venture - Series Unknown | Apr 13, 2022 |  |
| MediBuddy | MediBuddy is a digital healthcare platform for an inpatient hospitalization, outpatient services, and corporate wellness benefits.MediBuddy is the award-winning technology platform from Medi Assist that transforms the health insurance industry at the very core. MediBuddy, with its diverse offerings for various stakeholders of the health benefitsindustry, makes the process of discovering, accessing, utilizing, and monitoring health benefits seamless, real-time, and virtually paperless. The company was founded in 2000 and based in Bangalore, Karnataka, India. | $40M | Series B | Feb 02, 2021 |  |

4 of 4 investments shown.

## Co-investors
- [Bessemer Venture Partners](https://shizune.co/investors/profile/bessemer-venture-partners) — VC Fund, 3 deals together
- [ALES Global Japan](https://shizune.co/investors/profile/ales-global-japan) — VC Fund, 1 deal together
- [Beyond Next Ventures](https://shizune.co/investors/profile/beyond-next-ventures) — VC Fund, 1 deal together
- [FinSight Ventures](https://shizune.co/investors/profile/finsight-ventures) — VC Fund, 1 deal together
- [JIF Capital](https://shizune.co/investors/profile/jafco-asia) — VC Fund, 1 deal together
- [Milliways Ventures](https://shizune.co/investors/profile/milliways-ventures) — VC Fund, 1 deal together

## About InvAscent

VC Fund · Port Louis, Mauritius

InvAscent is the investment advisor to EILSF (Fund I), India Life Sciences Fund II (ILSF-II) and India Life Sciences Fund III (ILSF-III). These funds provide private equity growth capital to companies in the Indian pharmaceutical, healthcare, animal health and medtech industries. Examples of funds usage include capacity expansion, introduction ofnew products, acquisitions, etc. The typical investment size is in the range of USD 10 - 40 million over the life of the investment for a significant minority stake.

2 contacts available at InvAscent.

| Name | Title | Profile |
| --- | --- | --- |
| Hari Buggana | Founder, Chairman and Managing Director | https://shizune.co/investors/profile/hari-buggana-b899 |
| T.P. Devarajan | Managing Director | https://shizune.co/investors/profile/t-p-devarajan |

## Similar investors

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does T.P. Devarajan invest in?

T.P. Devarajan invests primarily in Health Care, Medical and mHealth startups, most often at Series B and Funding Round stage. Most of the 4 investments tracked by Shizune back companies in India. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact T.P. Devarajan?

Public channels for T.P. Devarajan include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### When did T.P. Devarajan last invest?

The most recent investment recorded for T.P. Devarajan closed in Apr 2022. Shizune tracks 4 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co